Verano Holdings (VRNO) Change in Accured Expenses (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Change in Accured Expenses of -$15.7 million for Q1 2026, down 74.1% year-over-year from -$60.7 million in Q1 2025, and down 489.04% quarter-over-quarter from $4.0 million in Q4 2025.
Verano Holdings (VRNO) Change in Accured Expenses (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Change in Accured Expenses for 6 consecutive years, with -$15.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 74.1% year-over-year to -$15.7 million; the TTM figure through Mar 2026 stood at -$12.2 million (up 31.07% YoY), while the FY2025 annual figure was -$5.5 million, up 67.69% from the prior year.
- Change in Accured Expenses eased to -$15.7 million in Q1 2026 per VRNO's latest filing, from $4.0 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $32.2 million in Q4 2022 and bottomed at -$18.0 million in Q3 2022.
- Historically, Change in Accured Expenses has averaged -$1.5 million across 5 years, with a median of -$5.2 million in 2023.
- On a YoY basis, Change in Accured Expenses climbed as much as 203.91% in 2022 and fell as far as 1092.79% in 2022.
- Verano Holdings' Change in Accured Expenses stood at $32.2 million in 2022, then slipped by 19.29% to $26.0 million in 2023, then slumped by 139.64% to -$10.3 million in 2024, then jumped by 139.21% to $4.0 million in 2025, then plunged by 489.04% to -$15.7 million in 2026.
- Business Quant data shows VRNO's Change in Accured Expenses at -$15.7 million in Q1 2026, $4.0 million in Q4 2025, and -$1.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Verano Holdings | 449.04 Mn | 363.85 Mn | 99.70 Mn | 157,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 157,000.00 |
| Jun 30, 2026 | 157,000.00 |
| Mar 31, 2026 | -15.72 Mn |
| Mar 31, 2026 | -15.72 Mn |
| Dec 31, 2025 | 4.04 Mn |
| Dec 31, 2025 | 4.04 Mn |
| Sep 30, 2025 | -1.43 Mn |
| Sep 30, 2025 | -1.43 Mn |
| Jun 30, 2025 | 939,000.00 |
| Jun 30, 2025 | 939,000.00 |
| Mar 31, 2025 | -9.03 Mn |
| Mar 31, 2025 | -9.03 Mn |
| Dec 31, 2024 | -10.31 Mn |
| Dec 31, 2024 | -10.31 Mn |
| Sep 30, 2024 | -1.61 Mn |
| Sep 30, 2024 | -1.61 Mn |
| Jun 30, 2024 | 3.29 Mn |
| Jun 30, 2024 | 3.29 Mn |
| Mar 31, 2024 | -8.33 Mn |
| Mar 31, 2024 | -8.33 Mn |